Emergent Biosolutions Inc (EBS) - News Archive

Emergent BioSolutions Secures $29 Million in Medical Countermeasure Orders: A Strategic Boost Amid Global Health Preparedness In an era where the capacities for rapid response to biological threats have become paramount...

In a pivotal moment for Emergent BioSolutions Inc. (NYSE:EBS), the company has finalized the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a transaction valued at approxim...

In a significant development for public health preparedness, Emergent BioSolutions Inc. recently announced the exercise of a contract option valued at approximately $20 million for the supply of BioThrax (Anthrax Vaccin...

Emergent BioSolutions Inc. a leading player in the biopharmaceutical sector, is intensifying its focus on biodefense preparedness through recent contract modifications with the U.S. government and operational restructur...

In recent developments concerning infectious disease management, Emergent BioSolutions Inc. has announced its participation in a clinical trial evaluating the safety and efficacy of brincidofovir (brand name TEMBEXA) in...

Emergent BioSolutions Takes Bold Steps to Expand NARCAN Access and Combat the Opioid Epidemic GAITHERSBURG, Md. In an unwavering commitment to addressing the nation s opioid epidemic, Emergent BioSolutions Inc. (NYSE: E...

Emergent BioSolutions Secures $100 Million Asset-Backed Loan Facility Amidst Strategic Financial RefocusGAITHERSBURG, Md. Oct. 02, 2024 In a significant move to bolster its financial standing and operational capabilitie...

In a move reflecting its unwavering commitment to public health, Emergent BioSolutions Inc. (NYSE: EBS) has recently secured significant funding to bolster its national preparedness initiatives. On September 26, 2024, t...

Emergent BioSolutions Awarded $41.9 Million for Advanced Development and Scaling of Ebola Treatment EbangaGAITHERSBURG, Md. Sept. 12, 2024nn Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences company known f...

In a decisive move aimed at bolstering its financial stability and operational trajectory, Emergent BioSolutions Inc. (NYSE: EBS), a prominent provider of critical public health products, has secured a $250 million term...

: Emergent BioSolutions, a global life sciences company that focuses on developing and manufacturing vaccines and therapeutics, has made significant strides in its financial strategy by successfully refinancing its debt...

Emergent BioSolutions Inc. a prominent player in the biopharmaceutical industry, is making significant strides in addressing the ongoing opioid crisis with its new and expanded initiatives aimed at promoting preparednes...

The rampant emergence of mpox, also known as monkeypox, has raised considerable public health concerns worldwide, particularly within Africa and other regions currently facing outbreaks. In a pivotal move to combat this...

Emergent BioSolutions Transfers Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals - A Strategic Move amid Changing Dynamics in the Pharmaceutical IndustryEmergent BioSolutions, a global specialty pharmaceutica...

In a significant move aimed at bolstering public health accessibility, Emergent BioSolutions Inc. (NYSE: EBS) has announced the opening of a new distribution center specifically dedicated to its NARCAN® Nasal Spray prod...

SERB Pharmaceuticals Expands Footprint in Medical Countermeasures with $75 Million Acquisition of RSDL Kit from Emergent BioSolutionsIn a significant move that strengthens its position in the pharmaceutical sector, SERB...

: Emergent BioSolutions Inc. is embarking on a strategic transition by divesting key assets, including its Reactive Skin Decontamination Lotion (RSDL) kit and its Baltimore-Camden manufacturing facility. This article hi...

Emergent BioSolutions Inc (NYSE: EBS) has seen a commendable performance this month, with shares reflecting a 0.55% increase, contrasting with the broader market trends. Several developments within the company and its e...

Emergent BioSolutions Inc. has recently unveiled a new opioid emergency awareness public education campaign aimed at equipping people nationwide with the necessary knowledge to save lives using the Lay, Spray, Stay meth...

In a recent announcement, Emergent BioSolutions, a renowned biopharmaceutical company, shared exciting news regarding the extension of the shelf-life for their NARCAN Nasal Spray in Canada. The decision to expand the ex...